Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CeCil trial in newly diagnosed MGMT-promoter unmethylated glioblastoma
2009-012324-83Phase 2Completed
- Sponsor
- Prof Bart Neyns
- Start
- Jul 2009
- Modality
- Modified Peptides → Peptides, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in glioblastoma (GBM) comparing Radiotherapy + temozolomide + cilengitide with Radiotherapy + temozolomide + cetuximab (2 arms). Primary endpoint: 1-year overall survival. Started Jul 2009; status: completed.
02
Drugs
cilengitidecetuximabtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2009-012324-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012324-83.